Profile data is unavailable for this security.
About the company
Kopran Limited is an India-based integrated pharmaceutical company. The Company is primarily engaged in the business of manufacturing of formulation (finished dosage form) and active pharmaceutical ingredients (APIs). Its formulations product categories include penicillin-based finished oral dosage forms and non-penicillin-based finished oral dosage forms. The Company's penicillin-based finished oral dosage forms include anti-infective, amoxycillin, ampicillin, cloxacillin and amoxy clauv. Its non-penicillin-based finished oral dosage forms include macrolides, anti-hypertensive, cardiovascular, anti-helmentics, antihistamine, anti-diabetic, pain management and gastroenterology. It provides ingredients in a wide range of pharmaceutical products, such as capsules, injectables and tablets, among others. The Company's APIs products include anti-hypertensive, macrolides, neuromodulator, urological, anti-infective/anti-acne, sterile carbapenems and sterile cephalosporins.
- Revenue in INR (TTM)6.15bn
- Net income in INR509.56m
- Incorporated1958
- Employees394.00
- LocationKopran LtdParijat House1076, Dr. E. Moses Road, Worli9917MUMBAI 400018IndiaIND
- Phone+91 2 243661111
- Fax+91 2 224950363
- Websitehttps://www.kopran.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Panacea Biotec Ltd | 5.59bn | -9.40m | 7.89bn | 1.09k | -- | 0.9373 | 22.41 | 1.41 | -0.16 | -0.16 | 91.52 | 137.48 | 0.4452 | 1.21 | 9.52 | -- | -0.1194 | 10.26 | -0.1597 | 16.53 | 58.85 | 52.88 | -0.2683 | 24.87 | 0.9948 | -15.86 | 0.0244 | -- | 21.57 | 4.13 | 96.48 | -- | 74.65 | -- |
| Bajaj Healthcare Ltd | 4.73bn | -143.27m | 8.16bn | 1.06k | -- | 2.93 | 61.41 | 1.72 | -5.18 | -30.36 | 171.62 | 100.86 | 0.5681 | 1.44 | 2.32 | -- | -1.72 | 6.97 | -3.51 | 12.73 | 46.18 | 30.16 | -3.03 | 7.20 | 0.8096 | 1.64 | 0.5446 | 5.38 | -29.69 | 5.04 | -133.30 | -- | 15.08 | -- |
| Jagsonpal Pharmaceuticals Ltd | 2.09bn | 224.63m | 8.86bn | 940.00 | 39.56 | 4.73 | 36.73 | 4.25 | 8.47 | 8.47 | 78.31 | 70.88 | 1.01 | 5.27 | 13.12 | -- | 10.90 | 10.95 | 12.30 | 13.29 | 55.00 | 58.17 | 10.76 | 9.21 | 9.63 | 26.29 | 0.0455 | 43.81 | -11.83 | 4.58 | -15.94 | 25.50 | -35.69 | 82.06 |
| Vimta Labs Ltd | 3.18bn | 410.09m | 10.79bn | 1.37k | 26.69 | 3.38 | 14.35 | 3.39 | 18.24 | 18.24 | 141.64 | 144.20 | 0.8349 | 3.23 | 3.81 | -- | 10.76 | 10.53 | 12.60 | 12.77 | 76.02 | 73.65 | 12.89 | 12.16 | 2.46 | 24.79 | 0.0566 | 11.15 | 0.0223 | 8.40 | -14.87 | 10.13 | 35.88 | 0.00 |
| Bliss GVS Pharma Ltd | 7.70bn | 754.54m | 11.02bn | 763.00 | 14.86 | 1.14 | 10.21 | 1.43 | 7.08 | 7.08 | 72.86 | 92.39 | 0.6498 | 3.45 | 1.95 | -- | 6.88 | 6.46 | 8.37 | 8.22 | 50.39 | 44.21 | 10.59 | 9.92 | 4.34 | 17.97 | 0.0905 | 7.93 | 2.48 | -3.03 | 6.49 | -9.42 | -8.33 | -12.94 |
| Syncom Formulations (India) Ltd | 2.63bn | 253.14m | 11.28bn | 799.00 | 35.29 | 3.91 | 37.55 | 4.28 | 0.34 | 0.34 | 3.56 | 3.07 | 0.6732 | 7.42 | 2.95 | -- | 6.47 | 7.50 | 9.00 | 10.23 | 40.44 | 34.59 | 9.61 | 9.38 | 2.38 | 5.57 | 0.201 | -- | 17.45 | 7.12 | 26.13 | 17.95 | -- | -- |
| Kopran Ltd | 6.15bn | 509.56m | 11.49bn | 394.00 | 22.70 | 2.34 | 18.00 | 1.87 | 10.50 | 10.50 | 126.95 | 101.90 | 0.8824 | 2.99 | 3.28 | -- | 7.32 | 8.47 | 10.22 | 12.23 | 34.60 | 34.18 | 8.29 | 8.89 | 1.44 | 43.23 | 0.168 | 25.41 | 11.54 | 11.42 | 87.11 | 16.23 | 12.53 | -- |
| Lincoln Pharmaceuticals Ltd | 5.81bn | 933.05m | 12.06bn | 1.70k | 12.92 | 2.03 | 11.60 | 2.08 | 46.58 | 46.58 | 289.81 | 295.98 | 0.9017 | 3.78 | 3.90 | -- | 14.49 | 13.95 | 16.61 | 16.54 | 52.06 | 51.21 | 16.07 | 14.71 | 4.01 | 60.95 | 0.0018 | -- | 13.76 | 9.66 | 27.99 | 13.88 | 21.54 | 3.71 |
| Remus Pharmaceuticals Ltd | 450.27m | 85.03m | 12.10bn | 38.00 | 128.53 | 46.58 | 134.76 | 26.88 | 15.98 | 15.98 | 90.25 | 44.09 | -- | -- | -- | 11,849,290.00 | -- | -- | -- | -- | 52.39 | -- | 18.88 | -- | 1.35 | -- | 0.2933 | -- | 82.17 | -- | 151.14 | -- | -- | -- |
| Beta Drugs Ltd | 2.56bn | 347.57m | 12.23bn | 315.00 | 35.18 | 8.61 | 26.72 | 4.78 | 36.15 | 36.15 | 266.28 | 147.68 | 1.24 | 4.44 | 3.72 | 8,126,721.00 | 16.85 | -- | 25.36 | -- | 41.88 | -- | 13.58 | -- | 1.43 | 18.21 | 0.098 | -- | 23.54 | -- | 23.73 | -- | -- | -- |
| Zota Health Care Ltd | 1.80bn | -143.48m | 13.39bn | 338.00 | -- | 14.50 | 233.12 | 7.42 | -5.59 | -5.59 | 70.40 | 34.81 | 0.9341 | 2.02 | 6.55 | -- | -7.42 | -1.38 | -10.54 | -1.85 | 46.43 | 36.48 | -7.95 | -1.33 | 0.7851 | -2.62 | 0.5143 | -- | 28.96 | 16.08 | -148.54 | -- | 39.85 | 0.00 |
| Windlas Biotech Ltd | 6.31bn | 581.87m | 13.81bn | 1.05k | 23.77 | 3.07 | 19.28 | 2.19 | 27.94 | 27.94 | 302.99 | 216.33 | 1.09 | 5.79 | 4.99 | -- | 10.07 | -- | 13.50 | -- | 37.21 | -- | 9.22 | -- | 2.15 | 58.58 | 0.008 | -- | 22.97 | -- | 36.51 | -- | -- | -- |
| Ngl Fine Chem Ltd | 3.39bn | 413.43m | 14.22bn | 343.00 | 34.39 | 5.41 | 26.85 | 4.20 | 66.92 | 66.92 | 548.61 | 425.11 | 1.05 | 4.51 | 4.36 | -- | 12.87 | 15.06 | 16.61 | 19.58 | 53.18 | 46.79 | 12.20 | 13.15 | 1.96 | 30.64 | 0.1218 | 3.06 | 21.79 | 17.20 | 101.58 | 15.47 | 14.49 | 0.00 |
| Holder | Shares | % Held |
|---|---|---|
| quant Money Managers Ltd.as of 31 May 2024 | 100.00k | 0.21% |
| American Century Investment Management, Inc.as of 09 May 2024 | 46.65k | 0.10% |
| Dimensional Fund Advisors LPas of 09 May 2024 | 29.97k | 0.06% |
| Dimensional Fund Advisors Ltd.as of 30 Apr 2024 | 819.00 | 0.00% |
| Motilal Oswal Asset Management Co. Ltd.as of 30 Apr 2024 | 308.00 | 0.00% |
